Goal 2: Reduce Human Disease

Submitted by (@serevill)

Does lowering circulating lipoprotein(a) levels influence cardiovascular outcomes?

A comprehensive research strategy and plan is needed to determine the most efficient, safe, cost-effective and widely applicable strategy to decrease circulating levels of lipoprotein(a) and to determine whether lowering circulating lipoprotein(a) levels will reduce the risk of developing cardiovascular disease such as a heart attack or a stroke as well as the progression of atherosclerosis or aortic stenosis.

Voting

235 net votes
297 up votes
62 down votes
Active

Goal 2: Reduce Human Disease

Submitted by (@jsullivan)

Prevent the Development of COPD

What can be done to prevent the development of COPD in individuals at increased risk. Quitting smoking before the development of COPD can prevent COPD development. What can be done to prevent COPD for individuals with other identified ris factors

Voting

15 net votes
18 up votes
3 down votes
Active

Goal 2: Reduce Human Disease

Submitted by (@nhlbiforumadministrator)

Reducing Atrial Fibrillation by treating modifiable risk factors

Would better management of modifiable risk factors, including obesity, sleep apnea, hypertension, hyperglycemia, and metabolic syndrome, reduce atrial fibrillation recurrence? Furthermore, what are the best methods to reduce the onset, hospitalization, and death due to atrial fibrillation, especially that associated with aging

Voting

3 net votes
18 up votes
15 down votes
Active

Goal 3: Advance Translational Research

Submitted by (@nhlbiforumadministrator)

ASCVD Risk and Treatment Options

There is little evidence about the best ways in which to effectively communicate atherosclerotic cardiovascular disease (ASCVD) risk to patients so that they clearly understand the potential benefits and harms of treatments in order to make informed decisions about their care. A shift toward shared decision-making and tailored treatment makes it imperative that effective risk communication strategies be developed and ...more »

Voting

-2 net votes
6 up votes
8 down votes
Active

Goal 2: Reduce Human Disease

Submitted by (@david.goff)

Should clinical primary prevention of ASCVD be guided by subclincal disease or estimated risk?

Current approaches to guiding use of clinical primary prevention interventions, e.g., statins and aspirin, are based on treating patients who exceed a specific risk threshold. The performance of risk estimation is good, but not outstanding, and results from clinical and population studies continue to support the value of new biomarkers. Given the widespread use of preventive therapies, the lack of untreated cohorts is ...more »

Voting

-3 net votes
6 up votes
9 down votes
Active

Goal 3: Advance Translational Research

Submitted by (@nhlbiforumadministrator)

Clinical Tools for Pediatric CVD Risk Reduction and Asthma Treat

What are effective strategies and clinical decision support tools that can maximize pediatric care providers’ adoption of evidence-based recommendations for assessment and treatment of cardiovascular risk factors and/or asthma? • Clinical recommendations and associated implementation tools are often incorporated into electronic medical records (EMRs). Currently there is no standard EMR format and therefore it is difficult ...more »

Voting

0 net votes
10 up votes
10 down votes
Active

Goal 2: Reduce Human Disease

Submitted by (@heit.john)

Identifying the High Venous Thromboembolism-Risk Individual

Over 500,000 incident or recurrent venous thromboembolism (VTE) events occur annually in the US. Almost one-quarter of acute pulmonary embolism patients suffer sudden death. To improve survival, the occurrence of VTE must be reduced. However, the incidence of VTE has increased over the last 30 years. Moreover, near universal prophylaxis of patients hospitalized for surgery or for medical illness has not reduced hospitalization-associated ...more »

Voting

2 net votes
18 up votes
16 down votes
Active

Goal 2: Reduce Human Disease

Submitted by (@leonardo.brandao)

Understand the Impact of Thrombosis in Children with Cancer

CC: Despite the potential impact that venous thrombotic events (VTE) have on children with cancer, several unresolved issues remain. To date, we are yet to understand: - incidence/prevalence of VTE according to cancer type/staging - ideal imaging modalities to diagnose/follow VTE - thromboprophylaxis according to thrombosis risk stratification (development of VTE predictors) - efficacy/safety to anticoagulate children ...more »

Voting

30 net votes
38 up votes
8 down votes
Active